found Documents: 350

Announcements & Press Releases, Oncology / Immunology | 23 Jan 2023

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

2 items

— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Eur

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Jan 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (�

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Jan 2023

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical tria

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 19 Dec 2022

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

2 items

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — F

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 15 Nov 2022

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

2 items

Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 14 Nov 2022

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

2 items

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant �

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 27 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 10 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm anti

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Sep 2022

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

2 items

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-b

View Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Aug 2022

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

2 items

— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Aug 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

2 items

San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in the United State

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

2 items

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

2 items

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — Hong Kong, Shanghai & Florh

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 1 Aug 2022

HUTCHMED Reports 2022 Interim Results and Provides Business Updates

2 items

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with hig

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Aug 2022

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, August 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient receiv

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 15 Jul 2022

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

2 items

— HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies — Hong Kong, Shanghai & Florham Park, NJ — Friday, July 15, 2022: HUTCH

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2022

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

2 items

— 49% ORR amongst SAVANNAH patients with higher MET levels — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 13, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Jul 2022

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

2 items

San Diego, Shanghai, Hong Kong and Sydney — Wednesday, July 6, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in Australi

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 27 Jun 2022

HUTCHMED to Announce 2022 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, June 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Jun 2022

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Pr

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group, Regulatory Notice | 30 May 2022

Notice of Publication of 2021 Sustainability Report

2 items

The English and Chinese versions of the 2021 Sustainability Report (the “Sustainability Report”) are available on the website of the Company at www.hutch-med.com and that of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk

HKEX Notification Letter (PDF)2021 Sustainability Report

Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 May 2022

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

2 items

HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT Hong Kong, Shanghai & Florham Park, NJ — Monday, May 2, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) anno

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 31 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 31, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 23 Mar 2022

2021 Annual Report and Notice of Annual General Meeting

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, March 23, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the For

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 11 Mar 2022

Update on Status under Holding Foreign Companies Accountable Act

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, March 11, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Account

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Mar 2022

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 7, 2022: (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED announces retirement of CEO and appointment of new CEO

2 items

Hong Kong, Shanghai & Florham Park, NJ – Thursday, March 3, 2022: (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces: the retirement of Mr. Christian Hogg after almost 22 years with the Company, including

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 3 Mar 2022

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

2 items

Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidne

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Mar 2022

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

2 items

— First homegrown innovative medicine approved in Macau based on China clinical data — Hong Kong, Shanghai & Florham Park, NJ –– Tuesday, March 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today an

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Group | 7 Feb 2022

HUTCHMED to Announce 2021 Final Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, February 7, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 4 Feb 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, February 4, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel sele

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jan 2022

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Thursday, January 20, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, hi

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 19 Jan 2022

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, January 19, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Jan 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 12, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Admin�

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 10 Jan 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

2 items

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 t

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 20 Dec 2021

HUTCHMED Included in FTSE Russell Indexes

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, December 20, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 14 Dec 2021

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 14, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63rd American Society for

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 10 Dec 2021

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalima

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Dec 2021

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

2 items

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study[1], and to support global registrations —

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Dec 2021

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Friday, December 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Adminis

LSE RNS Announcement (PDF)HKEX - INSIDE INFORMATION (PDF)

Announcements & Press Releases, Oncology / Immunology | 24 Nov 2021

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

2 items

— Follows important findings from the TATTON[1] study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 24, 2021: H

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Nov 2021

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, November 8, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be present

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Nov 2021

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

2 items

— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57% confirmed response rate in PRCC patients with

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Oct 2021

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Thursday, October 28, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational s

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

2021, Announcements & Press Releases, Oncology / Immunology | 29 Sep 2021

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

2021, Announcements & Press Releases, Group | 29 Sep 2021

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, September 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Sep 2021

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 21, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Sep 2021

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

2 items

— Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors — Hong Kong, Shanghai & Florham Park,

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Sep 2021

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Sep 2021

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

2 items

— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 8,

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

2 3 4 5 6 7